Mainz Biomed B.V. (MYNZ)
USD 3.78
(-14.48%)
USD 3.78
(-14.48%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.42 Million USD | 129.87% |
| 2022 | 3.22 Million USD | 25.3% |
| 2021 | 2.57 Million USD | -13.53% |
| 2020 | 2.97 Million USD | 23.44% |
| 2019 | 2.41 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q4 | 7.42 Million USD | -26.93% |
| 2023 Q2 | 8.53 Million USD | 130.26% |
| 2023 Q1 | 3.7 Million USD | 14.79% |
| 2023 Q3 | 10.15 Million USD | 19.02% |
| 2023 FY | 7.42 Million USD | 129.87% |
| 2022 Q2 | 2.48 Million USD | 0.0% |
| 2022 Q4 | 3.22 Million USD | 0.0% |
| 2022 FY | 3.22 Million USD | 25.3% |
| 2021 Q1 | 533.38 Thousand USD | -82.1% |
| 2021 FY | 2.57 Million USD | -13.53% |
| 2021 Q3 | 533.38 Thousand USD | -80.26% |
| 2021 Q4 | 2.57 Million USD | 383.02% |
| 2021 Q2 | 2.7 Million USD | 406.65% |
| 2020 FY | 2.97 Million USD | 23.44% |
| 2020 Q4 | 2.97 Million USD | 379.7% |
| 2020 Q3 | 621.11 Thousand USD | 0.0% |
| 2020 Q2 | 621.11 Thousand USD | 0.0% |
| 2020 Q1 | 621.11 Thousand USD | 26.62% |
| 2019 FY | 2.41 Million USD | 0.0% |
| 2019 Q4 | 490.51 Thousand USD | 0.0% |
| 2019 Q1 | 490.51 Thousand USD | 0.0% |
| 2019 Q2 | 490.51 Thousand USD | 0.0% |
| 2019 Q3 | 490.51 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bionano Genomics, Inc. | 87.94 Million USD | 91.562% |
| Prenetics Global Limited | 2.36 Million USD | -213.194% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -105.619% |
| CareDx, Inc | 34.22 Million USD | 78.315% |
| Exact Sciences Corporation | 2.55 Billion USD | 99.71% |
| Exagen Inc. | 23.72 Million USD | 68.716% |
| Inotiv, Inc. | 417.64 Million USD | 98.223% |
| Guardant Health, Inc. | 1.35 Billion USD | 99.452% |
| Biodesix, Inc. | 60.69 Million USD | 87.773% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -5463.012% |
| Precipio, Inc. | 1.11 Million USD | -564.944% |
| iSpecimen Inc. | 196.24 Thousand USD | -3681.405% |
| Natera, Inc. | 441.99 Million USD | 98.321% |
| Aspira Women's Health Inc. | 2.26 Million USD | -227.484% |
| Standard BioTools Inc. | 98.21 Million USD | 92.444% |
| 23andMe Holding Co. | 76.51 Million USD | 90.302% |
| Castle Biosciences, Inc. | 15.31 Million USD | 51.53% |
| Personalis, Inc. | 48.96 Million USD | 84.844% |
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -1641.967% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -499.533% |
| OpGen, Inc. | 13.04 Million USD | 43.108% |
| T2 Biosystems, Inc. | 49.49 Million USD | 85.008% |
| Myriad Genetics, Inc. | 145 Million USD | 94.882% |
| ICON Public Limited Company | 3.93 Billion USD | 99.812% |
| NeoGenomics, Inc. | 611.67 Million USD | 98.787% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -105.619% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 99.217% |
| RadNet, Inc. | 1.49 Billion USD | 99.502% |
| MDxHealth SA | 41.26 Million USD | 82.017% |
| Psychemedics Corporation | 2.29 Million USD | -222.923% |
| Illumina, Inc. | 2.26 Billion USD | 99.672% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 94.06 Million USD | 92.111% |
| DarioHealth Corp. | 29.54 Million USD | 74.88% |
| Fulgent Genetics, Inc. | 14.9 Million USD | 50.219% |
| Sera Prognostics, Inc. | 1.85 Million USD | -299.396% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -1781.522% |
| OPKO Health, Inc. | 326.56 Million USD | 97.728% |
| Medpace Holdings, Inc. | 142.12 Million USD | 94.779% |
| Neogen Corporation | 906.23 Million USD | 99.181% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -751.554% |
| Prenetics Global Limited | 2.36 Million USD | -213.194% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -370.075% |
| Trinity Biotech plc | 67.42 Million USD | 88.994% |
| Neuronetics, Inc. | 62.47 Million USD | 88.122% |
| Sotera Health Company | 2.32 Billion USD | 99.681% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -370.075% |